ReviewBioMed research international2013
Role of the microbiota and antibiotics in primary sclerosing cholangitis.
Review in BioMed research international, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03890536 (Intestinal Microbiome Composition in Infants With Biliary Atresia), which is not on this map. Cited by 51 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Intestinal Microbiome Composition in Infants With Biliary Atresia
Who cites it
51 citing papers in PubMed, 95 citations in OpenAlex.
- Prospective Clinical Trial of Rifaximin Therapy for Patients With Primary Sclerosing Cholangitis.American journal of therapeuticsTrial
- Gut microbiota in the development and progression of chronic liver diseases: Gut microbiota-liver axis.World journal of hepatology · 2025Review
- A Closer Look into Autoimmune Liver Diseases.International journal of molecular sciences · 2025Review
- Primary sclerosing cholangitis: a narrative review of diagnostic and prognostic biomarkers.Translational gastroenterology and hepatology · 2025Review
- Genetically predicted gut microbiota mediate the association between plasma lipidomics and primary sclerosing cholangitis.BMC gastroenterology · 2024Article
- Investigating the shared genetic architecture between primary sclerosing cholangitis and inflammatory bowel diseases: a Mendelian randomization study.BMC gastroenterology · 2024Article
- Absence of gut microbiota reduces neonatal survival and exacerbates liver disease in Cyp2c70-deficient mice with a human-like bile acid composition.Clinical science (London, England : 1979) · 2023Article
- Primary sclerosing cholangitis (PSC) and inflammatory bowel disease (IBD): a condition exemplifying the crosstalk of the gut-liver axis.Experimental & molecular medicine · 2023Review
- Colectomy in patients with ulcerative colitis is not associated to future diagnosis of primary sclerosing cholangitis.United European gastroenterology journal · 2023Article
- The Role of Microbiota in Liver Transplantation and Liver Transplantation-Related Biliary Complications.International journal of molecular sciences · 2023Review
- Small duct primary sclerosing cholangitis: A discrete variant or a bridge to large duct disease, a practical review.World journal of hepatology · 2022Review
- Gut Microbial Profile in Asymptomatic Gallstones.Frontiers in microbiology · 2022Article
- Effects of Intestinal FXR-Related Molecules on Intestinal Mucosal Barriers in Biliary Tract Obstruction.Frontiers in pharmacology · 2022Article
- Use of oral vancomycin in children with autoimmune liver disease: A single centre experience.World journal of hepatology · 2021Article
- Microbiota and viral hepatitis: State of the art of a complex matter.World journal of gastroenterology · 2021Review
- Bile Acids and Microbiota: Multifaceted and Versatile Regulators of the Liver-Gut Axis.International journal of molecular sciences · 2021Review
- Causal Linkage Between Inflammatory Bowel Disease and Primary Sclerosing Cholangitis: A Two-Sample Mendelian Randomization Analysis.Frontiers in genetics · 2021Article
- Emerging therapies in primary sclerosing cholangitis: pathophysiological basis and clinical opportunities.Journal of gastroenterology · 2020Review
- Review
- The search for the Holy Grail: autoantigenic targets in primary sclerosing cholangitis associated with disease phenotype and neoplasia.Auto- immunity highlights · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Primary sclerosing cholangitis (PSC) is an idiopathic, progressive, cholestatic liver disease with considerable morbidity and mortality and no established pharmacotherapy. In addition to the long-recognized association between PSC and inflammatory bowel disease, several lines of preclinical and clinical evidence implicate the microbiota in the etiopathogenesis of PSC. Here we provide a concise review of these data which, taken together, support further investigation of the role of the microbiota and antibiotics in PSC as potential avenues toward elucidating safe and effective pharmacotherapy for patients afflicted by this illness.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.